FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

Table 3 Patient characteristics in the propensity score-matched population according to first-line chemotherapy, n (%)

Characteristics	FOLFIRINOX (n = 96)	FOLFOXIRI (n = 96)	P value
Demographic parameters
Age, median [IQR], years	59.9 [53.0-66.9]	63.1 [55.2-67.1]	0.221
Missing	1	0
Gender			0.661
Male	54 (56.3)	57 (59.4)
Female	42 (43.7)	39 (40.6)
Familial history of cancer			0.806
No	31 (51.7)	51 (53.7)
Yes	29 (48.3)	44 (46.3)
Missing	36	1
Personal history of cancer			0.824
No	83 (88.3)	82 (87.2)
Yes	11 (11.7)	12 (12.8)
Missing	2	2
Pathologic parameters
Stage at diagnosis			0.598
Localized	14 (14.6)	12 (12.5)
Locally advanced	13 (13.5)	18 (18.87
Metastatic	69 (71.9)	66 (68.8)
Primary tumor site			0.385
Head	41 (42.7)	47 (49.0)
Body and/or tail	55 (57.3)	49 (51.0)
Histological grade			0.011
Well or moderately differentiated	36 (83.7)	24 (58.5)
Poorly differentiated or undifferentiated	7 (16.3)	17 (41.5)
Missing
Tumor extension
Stage at chemotherapy initiation			0.439
Locally advanced	14 (14.6)	18 (18.2)
Metastatic	82 (85.4)	78 (81.3)
Number of metastatic sites			0.724
0	14 (14.6)	18 (18.8)
1	57 (59.4)	53 (55.2)
≥ 2	25 (26.0)	25 (26.0)
Lymph node metastases			0.817
No	86 (89.6)	85 (88.5)
Yes	10 (10.4)	11 (11.5)
Liver metastases			0.274
No	26 (27.1)	33 (34.4)
Yes	70 (72.9)	63 (65.6)
Peritoneal metastases			0.059
No	84 (87.5)	74 (77.1)
Yes	12 (12.5)	22 (22.9)
Lung metastases			0.845
No	81 (84.4)	80 (83.3)
Yes	15 (15.6)	16 (16.7)
Other metastases			0.279
No	90 (93.8)	94 (97.9)
Yes	6 (6.2)	2 (2.1)
Clinical parameters
Performance status (WHO)			0.165
0	36 (39.1)	35 (36.5)
1	49 (53.3)	59 (61.5)
≥ 2	7 (7.6)	2 (2.0)
Missing	4	0
Body mass index, kg/m2	23.9 [20.7-27.1]	23.0 [21.2-25.0]	0.285
Missing	5	0
Pain			0.877
No	65 (67.7)	66 (68.8)
Yes	31 (32.3)	30 (31.2)
Jaundice			0.637
No	87 (91.6)	86 (89.6)
Yes	8 (8.4)	10 (10.4)
Missing	1	0
Ascites			1.000
No	92 (96.8)	92 (95.8)
Yes	3 (3.2)	4 (4.2)
Missing	1	0
Biological parameters
Albumin, median [IQR], g/L	39.6 [37.0-43.0]	34.6 [29.0-40.0]	0.001
Missing	40	51
Lymphocytes, median [IQR], mm3			0.157
< 1000	9 (11.2)	8 (21.0)
≥ 1000	71 (88.8)	30 (79.0)
Missing	16	58
Neutrophil-to-lymphocyte ratio, median [IQR]			0.072
< 5	63 (78.8)	24 (63.2)
≥ 5	17 (21.2)	14 (36.8)
Missing	16	58
CA19-9, median [IQR], UI/mL	857.5 [69.0-6210.0]	726.5 [152.0-5507.0]	0.500
Missing	2	20
Previous treatment
Primary tumor resection			0.284
Yes	10 (10.4)	15 (15.6)
No	86 (89.6)	81 (84.4)
Adjuvant chemotherapy			0.091
Yes	6 (6.2)	13 (13.5)
No	90 (93.8)	83 (86.5)

χ² tests or Fisher’s exact tests were used to compare proportions, and Wilcoxon tests were used to compare continuous variables between the FOLFIRINOX and FOLFOXIRI groups. All statistical tests were two-sided. CA19-9: Carbohydrate Antigen 19-9; IQR: Interquartile range; WHO: World Health Organization.